UMass Amherst Researchers Won $13.1M NIH Grant
Scientists are engineering salmonella to target drug-resistant breast cancer and improve immune system attacks.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Do you believe scientists should use bacteria to create new cancer treatments?
Researchers at UMass Amherst and Weill Cornell Medicine have received a $13.1 million grant from the National Institutes of Health. This funding will support five years of research into using engineered salmonella to treat drug-resistant triple-negative breast cancer.
Why it matters
This project aims to help the immune system bypass cancer evasion tactics while reducing the toxicity often associated with radiation therapy. It seeks to provide more precise treatment options for patients with difficult-to-treat triple-negative breast cancer.
The National Institutes of Health awarded a $13.1 million grant for a five-year study involving UMass Amherst and Weill Cornell Medicine. This preclinical research focuses on engineering microbes to deliver targeted therapies, though the project is not yet in human clinical testing.
The players
National Institutes of Health
The primary federal agency responsible for biomedical and public health research in the United States.
UMass Amherst
A public research university in Massachusetts that houses the primary scientific team investigating these novel cancer therapies.
Weill Cornell Medicine
An academic medical center and research institution collaborating on the development of new oncological treatments.
Ernest Pharmaceuticals
A biotechnology firm involved in the development of microbial therapies for cancer treatment.
The details
The research team plans to engineer salmonella to act as a delivery vehicle for cancer-killing viruses and radiopharmaceutical therapies. By coating tumor cells with a COVID-derived protein, the bacteria are intended to flag the cancer for a more robust immune system attack. This approach is designed to bypass the defensive evasion mechanisms typically used by triple-negative breast cancer cells while minimizing healthy tissue damage.
Timeline
October 5, 2026: UMass Amherst announced the NIH grant award.
Over the next five years: Research team will conduct the funded studies.
Health Landscape
This grant follows a trend in federal research funding toward exploring unconventional, bacteria-based delivery systems for targeted cancer therapies. It represents a shift away from systemic treatments toward modular, precision-guided microbial platforms.
This study is in the preclinical phase and does not currently change treatment options for patients. If you or a loved one are managing breast cancer, it is worth discussing the status of emerging clinical trials and new targeted therapy approaches with your oncologist.
The takeaway
This research is exploring how bacteria can be repurposed to deliver life-saving therapies directly to tumor sites. Patients should continue to monitor updates from their own physicians regarding new clinical trial opportunities as this research progresses.
Further reading
Learn more about the latest research and standard of care by visiting our Cancer section.
Live Poll
Do you believe scientists should use bacteria to create new cancer treatments?
